2011
DOI: 10.1111/j.1365-4632.2011.05056.x
|View full text |Cite
|
Sign up to set email alerts
|

Narrowband ultraviolet B (311 nm, TL01) phototherapy in chronic ordinary urticaria

Abstract: Narrow-band UVB (NB-UVB) therapy is an effective, well-tolerated treatment option in second-line therapy for COU. This therapy can lead to subjective relief of pruritus and whealing and objective reduction of whealing. Further larger studies with longer follow-up periods are necessary to determine the proper clinical response and long-term complications of this therapy in COU.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
24
0
2

Year Published

2013
2013
2024
2024

Publication Types

Select...
5
2
2

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(26 citation statements)
references
References 36 publications
(60 reference statements)
0
24
0
2
Order By: Relevance
“…Several studies have assessed the use of UVR therapy in urticaria (Table ). In general, UVR therapy appears to be helpful in reducing the symptoms of urticaria, with PUVA and UVA and also PUVA and NB‐UVB showing comparable results. Recently, both PUVA and NB‐UVB were effective in steroid‐dependent antihistamine‐refractory chronic urticaria, with NB‐UVB being statistically better .…”
Section: Uv Treatment In Mast Cell‐driven Diseasesmentioning
confidence: 98%
See 1 more Smart Citation
“…Several studies have assessed the use of UVR therapy in urticaria (Table ). In general, UVR therapy appears to be helpful in reducing the symptoms of urticaria, with PUVA and UVA and also PUVA and NB‐UVB showing comparable results. Recently, both PUVA and NB‐UVB were effective in steroid‐dependent antihistamine‐refractory chronic urticaria, with NB‐UVB being statistically better .…”
Section: Uv Treatment In Mast Cell‐driven Diseasesmentioning
confidence: 98%
“…Recently, both PUVA and NB‐UVB were effective in steroid‐dependent antihistamine‐refractory chronic urticaria, with NB‐UVB being statistically better . The use of different outcome measures such as visual analogue score, outcome scoring scale, urticaria activity score and quality of life impedes the direct comparison of studies …”
Section: Uv Treatment In Mast Cell‐driven Diseasesmentioning
confidence: 99%
“…The current EAACI/GA(2)LEN/EDF/WAO guidelines recommend using omalizumab, ciclosporin, or montelukast in patients who are unresponsive to up to fourfold dosed non-sedating antihistamines [3]. Additional therapeutics that have been tried in CSU include colchicine [37], mesalazine [38], hydroxychloroquine [39], dapsone [40,41], sulfasalazine [42], corticosteroids [43], narrowband ultraviolet B phototherapy [44], doxepin [45,46], mycophenolate mofetil [47,48], methotrexate [49][50][51], plasmapheresis [52], miltefosine [53], and intravenous immunoglobulin (IVIG) [54][55][56]. The vast majority of these have been used in small case reports and case series, but not in randomized controlled trials (RCTs) [ Table 1].…”
Section: Second-line Agents For Csumentioning
confidence: 99%
“…Other treatment options that have significant activity on mediator release on basophils include the calcineurin inhibitor cyclosporin A [5560], and occasionally ultraviolet therapy [5962]. As for immunosuppressive therapy with cyclosporin, a recent study suggests that history of hives, shorter duration of urticaria (mean of 55.2 weeks versus 259.6 weeks, P = 0.03), and CU index >10 ( P = 0.05) predict a favorable response to cyclosporin [60].…”
Section: Treatment Optionsmentioning
confidence: 99%